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Abstract: Canine progressive retinal atrophy (PRA) describes a group of hereditary diseases character-
ized by photoreceptor cell death in the retina, leading to visual impairment. Despite the identification
of multiple PRA-causing variants, extensive heterogeneity of PRA is observed across and within
dog breeds, with many still genetically unsolved. This study sought to elucidate the causal variant
for a distinct form of PRA in the Shetland sheepdog, using a whole-genome sequencing approach.
Filtering variants from a single PRA-affected Shetland sheepdog genome compared to 176 genomes
of other breeds identified a single nucleotide variant in exon 11 of the Bardet–Biedl syndrome-2 gene
(BBS2) (c.1222G>C; p.Ala408Pro). Genotyping 1386 canids of 155 dog breeds, 15 cross breeds and
8 wolves indicated the c.1222G>C variant was only segregated within Shetland sheepdogs. Out of
505 Shetland sheepdogs, seven were homozygous for the variant. Clinical history and photographs
for three homozygotes indicated the presence of a novel phenotype. In addition to PRA, additional
clinical features in homozygous dogs support the discovery of a novel syndromic PRA in the breed.
The development and utilization of a diagnostic DNA test aim to prevent the mutation from becoming
more prevalent in the breed.
Keywords: canine; PRA; retinal degeneration; BBS; BBS2; syndromic
1. Introduction
Inherited retinal degenerations (IRDs) represent a group of hereditary diseases associ-
ated with reduced retinal function, leading to visual impairment and eventually blindness.
In the domestic dog (Canis familiaris), progressive retinal atrophy (PRA) describes a group
of heterogeneous IRDs characterized by depletion of rod and cone photoreceptor cells
in the retina over time. The progression rate of PRA is variable, along with the etiology
and age of onset, which can be broadly defined as early or late onset. Upon ophthalmo-
scopic evaluation, clinical signs of PRA include the attenuation of retinal blood vessels,
widespread hyperreflectivity of the tapetum due to retinal thinning and atrophy of the
optic disc, revealing the presence of bilateral retinal degeneration. In later stages, cataracts
may develop secondary to the primary disease. PRA affects many dog breeds and is
considered a welfare concern as vision loss is inevitable. Canine PRA is akin to human re-
tinitis pigmentosa (RP) that affects 1 in 4000 humans worldwide [1], and shares phenotypic
similarities.
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Furthermore, many of the genes associated with canine IRDs have been implicated in
human IRDs. This genetic overlap, accompanied by similarities between the human and
canine eye morphology and size, means that the dog eye can be a useful model for human
retinal research. Naturally occurring canine models exist for several IRDs, some of which
have contributed to gene augmentation therapies in humans, such as the Rpe65 model for
Leber congenital amaurosis (LCA) [2], and the Pde6a [3] and Pde6b [4] models for autoso-
mal recessive RP phenotypes. Currently, 271 genes have been implicated in a variety of
human IRDs [5]. Human IRDs constitute several retinal disorders, including nonsyndromic
diseases, such as RP, and syndromic diseases, including Bardet–Biedl syndrome (BBS),
which involves a wide array of additional symptoms as well as retinal degeneration. Of
the reported human IRD genes, 35 genes are also associated with canine IRDs. Nine genes
are currently unique to canine IRDs but could be considered candidates for human IRDs.
Twenty-nine genes have been implicated in canine PRAs, including two genes previously
associated with human BBS [6,7]. Despite identifying many human and canine IRD genes,
many individuals of both species still lack a molecular diagnosis.
While the effectiveness of gene therapy has proven successful as a treatment for some
retinal degenerations in canine models, PRA is currently incurable. Therefore, the use
of DNA testing is crucial in controlling the disease in canine populations, offering dog
breeders a tool to determine their dog’s genotype for a specific PRA-associated variant.
This knowledge enables dog breeders to avoid breeding clinically affected puppies, even
before clinical signs of the disease become visible, as well as identify heterozygotes of a
recessive condition.
In the last decade, whole-genome sequencing (WGS) has become increasingly used
in disease variant identification to compare affected (case) and non-affected (control)
individuals. With WGS analysis, various filtering steps must be performed to strategically
decide which variants to consider for involvement with the disease. The use of canine
genome banks facilitates WGS analysis, enabling further variant filtration whereby, a single
genome can be used as a case in one study and a control genome for other studies. Although
the majority of canine PRA-associated variants found are located within coding regions
of the genome, disease-causing variants in non-coding areas have been identified [8–10].
WGS, as opposed to a targeted sequencing approach (including whole exome sequencing;
WES) enables the entire genome to be interrogated and provides a comprehensive dataset.
The British Veterinary Association/Kennel Club/International Sheep Dog Society
(BVA/KC/ISDS) Eye Scheme is a canine clinical eye screening scheme, which lists known
hereditary ocular diseases and the breeds affected with these conditions, based upon the
consistent opinion of veterinary ophthalmologists in the UK. Dogs intended to be used
for breeding are advised to undergo annual eye examinations to determine if they are
clinically affected or unaffected by the disease(s) listed for their breed. Before 2018, the
Shetland sheepdog (SS) was listed on this scheme as being affected by collie eye anomaly
(CEA) and PRA. Although the SS is no longer formally listed as being affected by PRA
under the scheme, the disease nevertheless remained a concern for the English SS Breed
Club in the UK when this genetic study was initiated because a small number of cases
had been identified through routine ophthalmoscopic screening. One form of PRA has
previously been described in the SS, caused by an exonic 4-base pair (bp) deletion in the
cyclic nucleotide gated channel α 1 gene (CNGA1) [11]. However, genetic heterogeneity had
been observed in the study cohort. Several SS unrelated to the CNGA1-affected proband
were genetically clear of the deletion, suggesting that at least one additional form of PRA
was segregating in the breed. This assumption was further supported when additional
SSs in the UK population were clinically diagnosed with PRA, yet were also genetically
clear of the CNGA1 deletion. Knowledge of non-CNGA1 forms of PRA in the breed, with
an unknown number of carriers in worldwide populations, warranted further study of
PRA to identify genetically unsolved cases. One PRA-affected SS was submitted to the
Kennel Club Genetics Center at the Animal Health Trust (AHT) for WGS analysis. This
study aimed to identify the genetic cause of a novel form of PRA in the SS, to both improve
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understanding of the etiology of this disease and enable the development of a DNA test
for breeders to use as a tool to reduce the frequency of, and eventually eradicate, a novel
form of PRA in the breed.
2. Materials and Methods
2.1. Sample Collection
PRA in the SS was diagnosed based on the ophthalmoscopic evaluation by a board-
certified veterinary ophthalmologist or a qualified BVA/KC/ISDS eye scheme panelist
(or the European equivalent if outside the UK). Buccal mucosal cheek swabs were used to
collect DNA from PRA cases and controls (approved by the AHT ethics committee; ref no.
24-2018E). Samples from a litter of three SS dogs, comprising one bitch (proband SS1) and
two dogs (probands SS2 and SS3), were submitted to the Kennel Club Genetics Center at
the Animal Health Trust due to a PRA diagnosis in the bitch. Control dogs were selected
as those aged 8 years and over that had been examined through the BVA/KC/ISDS eye
scheme and determined to be clinically clear of PRA. DNA was extracted from buccal
mucosal swabs using the QIAamp DNA Blood Mini Kit (Qiagen, Manchester, UK) accord-
ing to the manufacturer’s instructions. DNA concentration and purity were determined
using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Loughborough,
UK) and/or the Qubit Fluorometer with the Qubit dsDNA broad range (BR) assay kit
(Invitrogen, Loughborough, UK).
Additional SS samples were collected and genotyped for the candidate variant by The
University of Helsinki, Finland (n = 394) and The Norwegian University of Life Sciences,
Norway (n= 8). The University of Pennsylvania, USA generously shared DNA from a
family of nine SSs to also be genotyped for the candidate variant. Phenotype information
available for SS dogs concluded that: one PRA case, two SSs with suspected PRA, and
two SSs affected with other forms of retinopathy were present within The University of
Helsinki cohort; all eight SSs in The Norwegian University of Life Sciences cohort were
PRA cases, and one PRA case was present within The University of Pennsylvania DNA
samples.
2.2. Whole-Genome Sequencing (WGS)
Before WGS, 27 variants that were previously published and associated with canine
retinal diseases, including the CNGA1 variant identified in the SS breed, were excluded
as mutations responsible for this form of PRA in the SS, using a multiplex PCR followed
by sequencing or genotyping method (Table S1). Genomic DNA from a SS PRA case was
normalized to 25 ng/µL, and 1000 ng was sent for sequencing, outsourced to Edinburgh
Genomics, UK. Illumina sequencing of a TruSeq Nano library on a HiSeq X sequencing
platform (Illumina) generated a dataset of approximately 30x coverage of the dog genome.
Reads were aligned to the canine reference genome (CanFam3.1) using BWA-MEM [12],
variant calls were made using the Genome Analysis Tool Kit (GATK) v3.6 (HaplotypeCaller)
and base quality score recalibration, insertion/deletion (indel) realignment and duplicate
removal were performed [13]. SNP and indel discovery were performed using standard
hard filtering parameters or variant quality score recalibration according to GATK best
practice recommendations [14,15]. Genomic Variant Call Format (gVCF) files from 186
canine WGSs (in the AHT genome bank) were merged by CombineGVCFs (GATK) into a
multi-sample Variant Call Format (VCF) file. The cross-genome analysis was conducted
using Variant Effect Predictor (VEP) by Ensembl (Dog release 89) [16] on a merged VCF
file. WGS reads were visualized in Integrative Genomics Viewer (IGV) software [17].
Chromosomal positions of eight additional previously published PRA-associated variants
(Table S1) that were not screened prior to performing WGS were visualized in the SS WGS
data to determine genotypes.
Genes 2021, 12, 1771 4 of 19
2.3. Variant Filtering
An in-house effect score was assigned to each variant depending on its predicted
impact on the protein-coding sequence, and whether it was predicted to be deleterious
(Table S2). Variants were filtered for those with a high effect score (effect score 4 and 5),
including those resulting in premature start/stop codons, splice site variants, nonsense
and missense variants, frameshift variants and in-frame insertions and deletions. High
effect variants were initially filtered for those segregating as an autosomal recessive disease.
An X-linked dominant mode of inheritance was also considered by filtering high impact
variants on the X chromosome. Further variant filtering was conducted using the Dog
Biomedical Variant Database Consortium (DBVDC) [18] as a canine genome bank to filter
out common polymorphisms that were frequent across multiple dog breeds. Variants
were also prioritized based on the gene implicated and its candidacy. A list of keywords
related to PRA was compiled and cross-referenced through the OMIM database to extract
genes present in the WGS analysis that were associated directly or indirectly with any
words in the PRA keyword list (see File S1). This highlighted genes with previous evidence
of an association with ocular phenotypes and prioritized high impact variants based on
gene function. To assess the impact of the candidate variant amino acid substitution on
gene protein function, in silico bioinformatic tools Mutation Analyzer [19], PolyPhen-2
(Polymorphism Phenotyping v2) [20,21] and SIFT (Sorting Intolerant From Tolerant) [22]
were used to predict the effect of the identified variant computationally.
2.4. Extracting All Variants in BBS Genes
The syndromic phenotype of proband SS1 led to the exploration of potential genetic
correlates of BBS. To highlight additional variants in other genes associated with human
BBS, all variants regardless of their assigned effect score were extracted from the genomic
VCF file to a text file. The following ‘grep’ Unix command was used to extract all variants
that were located in 21 known BBS genes, including gene synonyms in the search: grep -
wE“(Chr|BBS1|BBS2|ARL6|BBS4|BBS5|MKKS|BBS7|BBS8|TTC8|BBS9|BBS10|
TRIM32|BBS12|MKS1|CEP290|WDPCP|SDCCA8|LZTFL1|BBIP1|IFT27|IFT172|
C8orf37|BBIP10)” input_file.txt > output_file.txt.
2.5. Variant Validation and Genotyping
The candidate single nucleotide variant (SNV) in BBS2 was confirmed using Sanger
sequencing. PCR products to be used for Sanger sequencing were purified on a MultiScreen
PCRµ96 filter plate (Merck Millipore, Watford, UK) and sequenced using the Sanger
method using Bigdye v3.1 chemistry (Life Technologies Ltd., Loughborough, UK) and the
following conditions: 96 ◦C for 30 s; 44 cycles at 92 ◦C for 4 s; 55 ◦C for 4 s; and 60 ◦C for
1 min 50 s. To remove excess reagents, isopropanol precipitation of sequencing reaction
products was performed. Precipitated DNA was resuspended in 10 µL Hi-Di Formamide
(Applied Biosystems, Loughborough, UK) and sequencing products were separated on
an Applied Biosystems (ABI) 3130xl Genetic Analyzer. Sequencing reads for each sample
were assembled using the Staden package [23]. The CEP290 SNV was genotyped using
PCR followed by Sanger sequencing, as described above.
An allelic discrimination probe-based assay was designed to effectively distinguish
between individuals that were homozygous for the BBS2 SNV (C/C), heterozygous (G/C)
or homozygous for the wild-type/common allele (G/G). Allelic discrimination assays
were performed using the following qPCR probes and primers: qPCR probe 1 5′-HEX-
ACACCATCATCCGAGCAGTACTGA- IBFQ -3′; qPCR probe 2 5′-FAM-ACACCATCATCC
GACCAGTACTGA- IBFQ -3′; primer 1 5′-CCATCTTGGACTGGTTCTTG; primer 2 5′-
CTGGAAAGGTTGTGAATGCT. Probes were PrimeTime ZEN double-quenched qPCR
probes containing a 5′ fluorophore, 3′ Iowa Black® FQ (IBFQ) quencher and proprietary
internal ZEN™ quencher. A 5′ HEX™ fluorophore was used to determine the reference
allele and a FAM™ fluorophore to label the alternate allele (purchased from Integrated
DNA Technologies (IDT); Leuven, Belgium) as PrimeTime assays. Real-time PCR was used
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to amplify template DNA using Luna universal qPCR Master Mix (New England Biolabs
(NEB) Ltd., Herts, UK) on a StepOnePlus™ real-time PCR system (ABI). The following
cycling parameters were used: 25◦ for 30 s, 95◦ for 3 min, 35 cycles of 95◦ for 3 s, 60◦ for 10 s
and a final post-PCR holding step at 25◦ for 30 s. Results were analyzed using ABI StepOne
Software v2.3 (ABI). The University of Helsinki, Finland, genotyped a cohort of SS dogs
(n = 394, including one PRA-affected SS; samples collected under the permission of the
Animal Experimental Board of Regional State Administrative Agency of Southern Finland,
ESAVI/7482/04.10.07/2015, ESAVI/25696/2020) using the allelic discrimination assay
described above. The Norwegian University of Life Sciences, Norway, also sequenced SS
PRA cases submitted to their research for the identified variant using the Sanger method
and primers and conditions described above. The University of Pennsylvania, USA also
provided DNA from SS to contribute towards variant validation.
3. Results
3.1. Phenotypes
Of the three related SSs in the original litter, a PRA diagnosis was confirmed in
probands SS1 and SS2 by a BVA/KC/ISDS panelist and/or veterinary ophthalmologist.
Proband SS1 was 8.7 years old at the time that the PRA diagnosis was confirmed. The
same proband had been examined under the BVA/KC/ISDS eye scheme 16 months earlier
(aged 7.4 years) by the same veterinary ophthalmologist and was clinically unaffected
at that time. PRA was diagnosed based on bilateral retinal degeneration findings due to
tapetal hyperreflectivity with retinal vascular attenuation and a pale optic disc. Menace
and pupillary light responses were present but reduced, and no cataracts were present.
Night blindness had been apparent for four weeks before the confirmed diagnosis and a
noticeable decline in daylight vision followed thereafter. A maze test was performed where
proband SS1 collided with obstacles under scotopic conditions but avoided obstacles under
photopic conditions. An extended profile electroretinogram showed depressed rod and
cone response. Ophthalmoscopic follow-up examination at 11.3 years reported no PRA
progression, but cataract formation at the equatorial region. Mature cataracts were present
bilaterally by the age of 12 years. Veterinary records showed that proband SS2 was also
diagnosed with retinal abnormalities consistent with PRA by a board-certified veterinary
ophthalmologist. This included tapetal hyperreflectivity and bilateral retinal blood vessel
attenuation at the age of six years. Although proband SS3 was not formally examined
through the BVA/KC/ISDS eye scheme or by a board-certified veterinary ophthalmologist,
a PRA diagnosis was suspected. The owners of proband SS3 reported that the dog started
to suffer visual impairment around the age of 9–10 years, initially presenting with reduced
vision in low light conditions, which progressed until his death at the age of 15 years. The
dam of the litter was examined under the BVA/KC/ISDS scheme at 11.4 years and was
clinically unaffected. There is no evidence that a veterinary ophthalmologist examined the
sire’s eyes.
Veterinary history regarding weight was only available from the age of 11 years for
proband SS1. Weight was recorded from the age of 11 years until euthanasia at the age
of 13.9 years, ranging from 5.1 kg–6.6 kg (normal range for the breed is 6.8 kg–11.3 kg),
with the owner reporting that the dog had been on a low-fat diet since her earlier years.
Proband SS2 was deemed obese, weighing 19.5 kg at the age of 5.5 years. The owner
reported that proband SS2 had a severely increased appetite and described the dog as
‘ravenous’ when offered food. A low-fat diet eventually reduced the dog’s weight to 14 kg
at the age of 6.4 years, but this was not maintained, resulting in subsequent weight gain. A
dirlotapide-based drug was used from the age of 5.9 years in an attempt to reduce body
weight. No information on the weight of proband SS3 was available.
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Limited information was available on renal biochemistry for proband SS1. However,
nephroliths were present at 13.3 years of age and eventually the owner elected for euthana-
sia at 13.9 years due to renal failure. For proband SS2, urea and creatine levels were within
normal limits at 5.5 years of age: 7.9 moles per liter (mol/L) (normal range 2.5–9.6 mol/L)
and 85 mol/L (normal range 44–159 mol/L), respectively. When assessed at 8 years of age,
these levels had increased (urea 26.7 mol/L; creatine 160 mol/L). Two months later, urea
and creatine levels had increased dramatically to 35.6 mol/L and 258 mol/L, respectively,
resulting in renal failure. The veterinarian prescribed a renal diet feed and Fortekor® to
aid in the management of chronic renal failure. By the age of 9.4 years, kidney disease had
progressed with elevated urea and creatine levels (urea 46.4 mol/L; creatine 444 mol/L)
and the owner elected for euthanasia. No information on the renal health of proband SS3
was available.
Proband SS1 showed uncharacteristic features for the breed, including an upturned
nose, an abnormal coat of a wavy texture and dental abnormalities (Figure 1). These features
became increasingly noticeable as the dog developed, becoming more apparent around
the age of six months. Veterinary history also noted dental remarks where multiple teeth
were extracted at the age of 11.9 years as lower incisors were loose. No further information
on the physical appearance of proband SS2 was available, although the dog was reported
to have undergone dental treatment of three teeth extractions due to resorptive lesions.
Similarly, no further information was available on the physical appearance of proband SS3.
Photographs of both sire and dam show they did not exhibit the unusual nose shape or
coat texture observed in the affected offspring.
Figure 1. Photographs of PRA-affected proband SS1 in the initial litter show the uncharacteristic ‘wavy’ coat, upturned
nose and dental defects (A–C).
3.2. WGS Variant Filtering
The exclusion of 35 previously published canine retinal mutations, including the
CNGA1 SS variant, indicated the presence of a novel PRA-associated mutation. At the time
of the study, 185 canine genomes, sequenced as part of other studies in our laboratory were
available for WGS analyses. The merged VCF file contained 186 genomes (1 case versus 185
controls) with a total of 27,611,812 variants amongst all genomes. Of these 185 genomes, 176
were of dogs recruited for non-PRA studies, and these were considered PRA controls for the
purposes of this study. Filtering for variants present in the 176 PRA control genomes and
with a high effect score (4 or 5) retained 136,383 high impact variants. As the litter consisted
of one PRA-affected female, one PRA-affected male and one male suspected to be affected
with PRA, an X-linked dominant mode of inheritance was considered. However, as the sire
was unaffected and the dam was clinically confirmed as unaffected, an X-linked dominant
PRA was unlikely. Nevertheless, IGV software was used to visualize sequencing reads from
proband SS1 over the entire RPGR gene, which has previously been implicated in canine
X-linked PRA [24]. No variants of interest were present in RPGR. In addition, no high
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impact variants segregated appropriately for an X-linked mode of inheritance (dominant or
recessive) or were present in six genes associated with X-linked RP in humans: RP2 [25,26],
OFD1 [27–29], TIMM8A [30], CACNA1F [31,32] and NYX [33–35]. Thus, an X-linked model
was excluded, and an autosomal recessive mode of inheritance was considered most
likely. Filtering based on an autosomal recessive model, i.e., retaining high effect variants
homozygous in proband SS1 and either heterozygous or homozygous for the alternate
allele in all 176 non-breed matched controls, resulted in 151 variants.
Exclusion of variants located on unknown chromosomes further narrowed the variant
list down to 134 variants. These 134 variants were checked across canine genomes in the
DBVDC, which comprised of 648 genomes at the time of the study (32 belonging to the
AHT), including three SS genomes. After filtering out common SNVs, 12 variants remained
that were all homozygous in the SS case and were absent from all other genomes in the
DBVDC (Table S3). Assessing the genes harboring these 12 variants in the OMIM database
against a list of keywords considered to be associated with PRA phenotypes resulted in
one deleterious variant in a gene associated in human IRDs (BBS2).
In parallel with screening the DBVDC, all genes in which the 151 variants were lo-
cated were assessed for their candidacy: 74 annotated genes (80 variants) and 40 Ensembl
canine stable identifiers (ENSCAF IDs; 71 variants). Of the 40 ENSCAF IDs, human ho-
mologues could be determined for ten genes (28 variants). Fifty-seven variants located
within ENSCAF IDs of which no human orthologous region was present and/or those on
unknown chromosomes were excluded. Therefore, a total of 84 gene names (accounting for
94 variants) were investigated in the OMIM database against a list of keywords considered
to be associated with PRA phenotypes. Thirty-eight variants were predicted to be tolerated
by SIFT and 37 variants were homozygous in multiple non-SS or non-Collie breed control
genomes in the DBVDC and were therefore excluded. The remaining 19 variants were man-
ually visualized in IGV following de novo local realignment using HaplotypeCaller [36],
which confirmed that 14 variants were called correctly by variant annotation tools (Table
S4). All 14 variants were investigated further.
3.3. Variant Mining
The 14 variants identified in the variant filtering process were genotyped across a
cohort of 43 SS controls, which were aged 8 years or older and diagnosed as clinically
unaffected by PRA. PCR amplicons could only be generated for 12 variants, among which
11 were homozygous in at least one of the SS controls and therefore were excluded as
causal PRA variants. Two PCR amplicons failed sequencing, probably due to difficulty in
amplification due to repetitive sequence and/or a GC-rich sequence. These were variants in
the genes C7 and IRS2. RNA sequencing (RNA-seq) data generated for an unrelated study
from a PRA non-affected Petit Basset Griffon Vendéen canine retina [37] showed C7 and
IRS2 were considered to be highly expressed in the canine retina. Although genotyping-by-
sequencing of the C7 and IRS2 variants failed, the variants were identified in additional
breeds in the DBVDC genomes. The variant in C7 was present in two SS control dogs in
homozygous and heterozygous states and was also heterozygous in WGS from a Lancashire
heeler dog. No sequencing data were available for the IRS2 variant in multiple genomes
and two Dachshund dogs were heterozygous for the insertion. Table S4 summarizes the 14
variants and determines whether they could be excluded as candidate variants or not. One
candidate variant is a homozygous missense SNV in the Bardet–Biedl syndrome 2 (BBS2)
gene (Figure 2), situated on canine chromosome 2 (CANFA2). Although the variants in
GGN, C7 and IRS2 could not be entirely excluded in control SSs using PCR methods, the
candidacy of BBS2 warranted prioritization of the BBS2 SNV for further exploration.
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Figure 2. IGV display of WGS reads aligned across the BBS2 c.1222G>C SNV region. Grey horizontal
bars show paired-end sequencing reads aligned to the canine reference genome across the BBS2
exon 11 location. Above these sequencing reads is a histogram representing sequencing coverage
across the region. Track (A) shows the WGS reads from the PRA-affected SS (proband SS1). The
blue block shows a homozygous SNV change from the reference nucleotide ‘G’ to a ‘C’ at position
chr2:59693737. Track (B) shows WGS data from a PRA non-affected control genome (Hungarian
Vizsla dog) that is homozygous for the reference ‘G’ allele. BBS2 is expressed in retinal tissue as
demonstrated by RNA-seq alignment from two control dogs: one Dalmatian dog (track (C)) and one
Petit Basset Griffon Vendéen (PBGV) dog (track (D)), both of which are also homozygous for the
reference allele at this position.
3.4. BBS2 c.1222G>C Missense Variant
Sanger sequencing confirmed the c.1222G>C missense SNV in exon 11 of BBS2
(Figure 3). This non-synonymous variant results in an amino acid change from alanine
to proline at amino acid position 408, p.(Ala408Pro). Mutation Analyzer and PolyPhen-2
predicted the BBS2 c.1222G>C, p.Ala408Pro amino acid change to be rarely substituted and
probably damaging to the protein, respectively (PolyPhen-2 score 0.993). SIFT predicted
the change to be deleterious with a score of 0.03.
Figure 3. Sanger sequencing of the BBS2 c.1222G>C variant confirmed its presence in proband SS1
(track (A)). Additional dogs were also homozygous for the c.1222G>C variant (tracks (B,C)). SSs
heterozygous for the variant and homozygous for the wild-type allele (G/G) are shown in tracks (D)
and (E), respectively.
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3.5. BBS2 c.1222G>C Population Screening
To better understand the frequency and predicted causality of c.1222G>C, the variant
was searched in: (a) different SS cohorts; (b) in SS PRA cases clear of the CNGA1 mutation
and non-affected cases; (c) in different breeds of dogs. In total, c.1222G>C was genotyped
across 1386 canids of 155 dog breeds, 15 cross breeds and 8 wolves (Table S5). This included
505 SS, of which 91 were submitted directly to the AHT research database. Frequencies of
the c.1222G>C variant in tested SS cohorts are detailed in Table 1.
Table 1. Frequencies of the BBS2 c.1222G>C variant in various SS cohorts. ‘G’ represents the
wild-type/common allele, ‘C’ represents the alternate allele.
Cohort c.1222G>C C/C c.1222G>C G/C c.1222G>C G/G Total SSGenotyped
AHT 5 11 75 91
The University of




2 0 6 8
The University of
Pennsylvania 0 0 9 9
DBVDC 0 0 3 3
Total SS genotyped 505
Taken together with the AHT cohort, a total of 14 SS were confirmed PRA cases, with
four individuals homozygous for the c.1222G>C variant (probands SS2 and SS3 from the
AHT original litter; two SS from the Norwegian cohort), and ten were homozygous for the
reference/common allele (G/G). Pedigree information from the two homozygous dogs
from the Norwegian cohort showed that they were non-related within five generations
to the original WGS case. No photographs or information were available regarding any
additional phenotypic information. All genotypes of SSs tested for the c.1222G>C variant
are summarized in Table 2. This constitutes dogs that were either confirmed PRA cases,
controls known to be PRA non-affected or dogs with an unknown PRA diagnosis.
Table 2. Genotype distribution of the BBS2 c.1222G>C SNV in SS confirmed PRA cases and non-affected controls or SS with
an unknown PRA diagnosis.
Confirmed PRA Cases PRA Non-Affected Unknown PRA Diagnosis
c.1222G>C
genotype C/C G/C G/G C/C G/C G/G C/C G/C G/G
Number of
individuals 4 0 10 2
† 11 29 1 6 442
† These PRA non-affected dogs that are homozygous for the BBS2 c.1222G>C SNV are aged 1 year and 7.6 years old. Due to the late-onset
nature of this form of PRA, these dogs will probably develop PRA in their lifetimes. Both dogs presented with additional characteristics of
the BBS2 phenotype (see probands SS4 and SS5 in Table 4).
Of the 858 dogs of non-SS breeds genotyped for the variant, 136 were Border Collie
dogs, including six PRA cases. These were, and remain, genetically unsolved, with the
c.1222G>C variant only identified in SSs in the present study. As genotyped in this study,
allele frequencies for the c.1222G>C variant are summarized in Table 3.
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Table 3. Allele frequency of BBS2 c.1222G>C SNV in multiple breeds of dog. ‘G’ represents the wild-type/common allele,
‘C’ represents the alternate allele.
Breed
c.1222G>C Genotype Allele Frequency of
Causal AlleleC/C G/C G/G
SS 7 17 481 0.031
SS * 4 13 481 0.021
Crossbreeds 0 0 15 0
Wolves 0 0 8 0
154 other breeds 0 0 858 0
* Excluding third-generation relatives to the proband.
3.6. Characterization of the BBS2-PRA Phenotype
Genotyping of two SSs, aged 1 year and 7.6 years old, with the same distinctive
characteristics as the initial case (upturned nose, unusual coat and dental defects) re-
vealed that both are homozygous for the c.1222G>C variant. The 7.6-year-old underwent
an ophthalmoscopic examination by a board-certified ophthalmologist (who was also
a BVA/KC/ISDS panelist), however no clinical signs of PRA were observed. Pedigree
information for these two additional homozygotes showed that both dogs share common
ancestry with probands SS1, SS2 and SS3 in the initial SS litter (Figure S1). The pedigree also
highlighted third-generation relatives of the proband, which were excluded in determining
allele frequencies so that the data were more representative of the general SS population.
Phenotype information for the seven homozygous SSs is summarized in Table 4,
demonstrating shared phenotypic features in addition to the PRA phenotype to characterize
the BBS2-PRA phenotype.
Table 4. Summary of the SS homozygous for the BBS2 c.1222G>C variant and their phenotypes.
Proband Ocular Phenotype Age of Diagnosis Age at Submission Additional Phenotypic Features





- On a low-fat diet but weight
managed
SS2 PRA confirmed 6 years 9 years
- No photographic evidence
available for physical
characteristics
- Weight issues (clinically
obese) and severely
increased appetite
- Kidney health issues
SS3 PRA unconfirmed butblind 9–10 years 9 years
- No photographic evidence
available for physical
characteristics
- No clinical history regarding
renal or weight status
available
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Table 4. Cont.
Proband Ocular Phenotype Age of Diagnosis Age at Submission Additional Phenotypic Features




- No clinical history regarding
renal or weight status
available




- Severely increased appetite
- Possible fertility disorder
- No clinical history regarding
renal status available
SS6 PRA confirmed Unknown Unknown
- No photographic evidence
available for physical
characteristics
- No clinical history regarding
renal or weight status
available
SS7 PRA confirmed Unknown Unknown
- No photographic evidence
available for physical
characteristics
- No clinical history regarding
renal or weight status
available
3.7. Additional BBS Gene Variants
Multiple BBS-associated variants have been described in human cases, including bial-
lelic and monoallelic variants, with heterozygous variants in up to three genes (reviewed
by [38]). To assess whether an oligogenic phenotype was manifesting in the affected SS, any
variants (regardless of their predicted effect on the coding sequence) residing in one of the
21 genes known to be implicated in human BBS were extracted for further investigation. A
total of 510,752 variants were present in the VCF output file for the genome of proband SS1,
of which 174 variants met these criteria. Of the 174 variants, 3 variants were situated in
the 3′ untranslated region (of BBS10), 17 were intergenic variants and 152 intronic variants.
The only exonic variants were the c.1222G>C SNV in BBS2, present only in the SS, and a
missense variant in CEP290 (c.3011G>A; p.(Ser1003Leu)). The CEP290 SNV was homozy-
gous in three additional breeds in the AHT genome bank (one Border Collie crossbreed,
one Bulldog and one Smooth Collie) and homozygous and/or heterozygous in 19 dogs
of 14 breeds in the DBVDC. The CEP290 SNV was also present in dbSNP (rs851859358)
with a minor allele frequency of 0.021, yet no phenotype information was available. The
variant was tolerated by SIFT with a score of 0.26. Five SSs homozygous for the BBS2
c.1222G>C variant, one heterozygous SS and one SS homozygous for the wild-type allele
were genotyped for the CEP290 SNV; all were homozygous for the alternate ‘A’ allele at
this position.
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4. Discussion
WGS analysis of a single PRA-affected SS, compared to 176 non-breed matched control
genomes, revealed a SNV in the BBS2 gene located on CANFA2. The BBS2 c.1222G>C
SNV segregated appropriately for an autosomal recessive disorder in the SS breed, with
a predicted severe impact on the protein. Genotyping of additional dogs demonstrated
that the SNV was not observed in any other breeds, indicating the variant was supposed to
be private to the SS breed. Further to proband SS1 sent for WGS, additional c.1222G>C
homozygous SS were identified, including two full siblings to the proband. Where available,
clinical information and photographs confirmed a PRA diagnosis and/or additional clinical
features. The involvement of BBS2 in human BBS patients sharing similar clinical features
presents BBS2 as a compelling candidate gene for a novel syndromic form of PRA in the SS.
Human BBS is classically an autosomal recessive multisystem ciliopathy. There is a
wide array of clinical manifestations whereby a BBS diagnosis is based on the presence of at
least four primary features, or three primary and two (or more) secondary features [39]. In
human patients, primary features of the condition include retinal degeneration, polydactyly,
obesity, genital abnormalities, renal abnormalities and learning difficulties. A diverse
spectrum of secondary features manifest, including speech and developmental delays,
diabetes, dental defects, congenital heart disease, brachydactyly and polydactyly, ataxia
and craniofacial abnormalities, including an abnormally high arched palate and depressed
nasal bridge [39]. While human BBS phenotypes are characterized by loss of function
mutations in 24 genes [40], all involved in the primary cilia functioning, many encoding
genes involved in BBS specifically regulate the machinery of the multi-subunit complex,
termed the BBSome. The BBSome consists of eight highly conserved proteins, BBS1-9 and
BBS18/BBIP10, which function in primary cilium biogenesis [41,42]. BBS proteins control
the formation of the primary cilia by facilitating cargo movement between plasma and
ciliary membranes. This process occurs across various cell types where primary cilia are
present, including the retina and kidneys. The BBS2, BBS7 and BBS9 proteins form the
BBSome core complex, which is essential in BBSome maturation [43]. Structurally, BBS2,
BBS7 and BBS9 are homologous proteins that share distinct protein folding and domain
organization [44]. Within the BBS2-7-9 subcomplex, BBS2 is located between BBS7 and
BBS9 with the α-helical domain of BBS2 in contact with BBS9 [45].
The canine BBS2 gene encodes a 715 amino acid protein with three domains (Figure
S2). The N-terminal is predicted to be positioned from amino acid residues 22–120; a
mid-terminal from 159–266 and a C-terminal from 270–709 (Pfam; [46]) with a putative
coiled-coil domain between 317–344 amino acid residues [47]. The c.1222G>C; p.Ala408Pro
SNV identified in the SS PRA case resides within the predicted C-terminal domain of BBS2.
BBS2 is conserved across species showing 90% sequence similarity to the human orthologue.
Additionally, the ‘GCA’ codon implicated is well conserved across 37 mammals, including
humans. Variants in BBS2 are associated with BBS [48–50] and nonsyndromic RP [51] in
humans, and have been implicated in retinal phenotypes in mice [52] and zebrafish [53]. To
date, 94 pathogenic or likely pathogenic variants and 158 variants of unknown significance
(VUS) have been reported in BBS2 in humans [54]. The canine p.Ala408 is at the orthologous
region in the human BBS2 gene p.Ala414, and although no pathogenic/likely pathogenic
variants have been reported at this position, three pathogenic/likely pathogenic variants
have been reported in exon 11, including a nonsense SNV at c.1237C>T (p.Arg413Ter) [55].
The BBS2 p.Ala408Pro in the present study is predicted to be positioned within the C-
terminal of BBS2. Variants reported within the human BBS2 C-terminal include a BBS2 mu-
tation causing an amino acid substitution of arginine to proline at residue 632 (p.Arg632Pro)
reported in BBS patients [55–57]. Binding experiments of the p.Arg632Pro substitution
revealed that the mutation is located in the α-helical domain of BBS2 [45]. Ludlam et al. [45]
demonstrated that BBS2 interacts with BBS7, forming a tight dimer that associates with
the rest of the BBSome hexameric subcomplex (comprised of BBS1, 4, 5, 8, 9, 18). There-
fore, the p.Arg632Pro substitution likely causes BBS because of an inability of the BBS2/7
dimer to bind to BBS9 and the rest of the BBSome [45]. Thus, considering the results of
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aforementioned studies establishing the presence of the α-helical domain of BBS2 within
the C-terminal [45,57], it may be hypothesized that this candidate SNV results in a loss of
function of BBS2 in the canine BBS2-7-9 complex, disrupting BBSome assembly, which may
impact ciliary transport machinery in the complex.
Retinal photoreceptor primary cilia and outer segments are essential for phototrans-
duction and maturation of the RPE, suggesting that the c.1222G>C variant impairs retinal
function through dysfunction of the phototransduction cascade. We described SSs diag-
nosed with bilateral retinal degeneration based on a PRA-like appearance, and additional
c.1222G>C homozygotes were also clinically affected with PRA. Exceptions to this include
proband SS3 in the initial litter, which was reported blind with PRA-like symptoms by
the owner but was not confirmed by a veterinary ophthalmologist. In addition, the two
SSs later identified as c.1222G>C homozygotes were unrelated within three-generations
to probands SS1, SS2 and SS3, aged 1 year and 7.6 years. Where a PRA diagnosis was
made, the age of onset varied. Therefore, both the 1-year-old and 7.6-year-old c.1222G>C
homozygotes will most likely develop this form of PRA within their lifetimes. Routine
ophthalmoscopic follow up of c.1222G>C homozygotes will determine disease age of onset
and progression. In addition to PRA, dogs harboring two c.1222G>C alleles showed a dis-
tinctive upturned nose, which is uncharacteristic of the breed, possibly due to a depressed
nasal bridge as described in human BBS [39]. Other subtle craniofacial secondary features
of human BBS include undeveloped cheekbones (malar hypoplasia), deep-set eyes with
short or narrow palpebral fissures, a wide forehead and jaw malformations [39,58,59], for
which clinical data for these features were unavailable for the SSs in this study. Notably, at
least some of the c.1222G>C homozygous dogs were on a low-fat diet for much of their
adult life, with one classed as severely obese. Furthermore, one case showed signs of
increased motivation for food, described by the owner as having a “voracious” appetite.
Due to limited clinical information, there is insufficient evidence to support the hypothesis
of an association between the BBS2 c.1222G>C variant and an increased appetite or obesity.
However, it is plausible that these dogs have dysregulation of satiety hormones, such as
leptin due to dysfunction of BBS2 in the BBSome, resulting in leptin resistance and therefore
an increased food intake leading to weight gain, as demonstrated in BBS knockout mouse
models [60,61]. Further study may determine whether weight is a contributing factor or
whether the c.1222G>C homozygotes were overweight due to overfeeding. Primary cilia,
on the surface of the nephron’s epithelial cells and collecting duct in the renal cortex of
the kidney, plays a role in epithelial homeostasis and repair. Furthermore, human BBS
patients with variants in the genes encoding the BBS2-7-9 complex have a high frequency
of kidney anomalies, suggesting this complex is more critical for the kidney’s function
and development than other BBSome components [40]. Information on kidney health was
not available for all probands in the study. However, kidney malfunctions were observed,
including one SS being on a kidney support diet and medication for renal disease. Potential
renal defects may be explained by ciliogenesis in the kidneys and the specific role of the
BBS2-7-9 complex. All additional features mentioned above are shared amongst human
BBS phenotypes [38,62–65]. The exception to this is the abnormal hair phenotype exhibited
in SSs, which could be due to primary cilia’s involvement in hair follicle development
and homeostasis. Relatable findings have been demonstrated in the Oak Ridge Polycystic
Kidney (ORPK) mouse as a model for cystic kidney disease and cilia dysfunction, whereby
ORPK mice display a scruffy fur phenotype in addition to renal defects, retinal degenera-
tion due to a loss of photoreceptor outer segments, polydactyly and other similarities to
severe BBS (dental crowding, abnormal palatal morphology, skeletal defects) (reviewed
by [66]). Therefore, further study of the BBS2 canine phenotype is required to understand
the array of clinical manifestations described in the SS PRA cases.
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Previous research demonstrates similarities between BBS-null mice and canine PRA
phenotypes, specifically in the Hungarian Puli dog where a nonsense SNV in BBS4 causes a
novel syndromic PRA [7], with phenotypes comparable to Bbs4-null mice [50]. In addition
to PRA, BBS4-affected Hungarian Puli dogs displayed spermatozoa flagella defects, albeit
less severely affected than that observed in Bbs4-null mice, as well as obesity. This was
the first BBS-like phenotype reported in dogs. Before this, the only BBS gene implicated
in canine PRA was the TTC8 gene, also known as BBS8, in Golden Retriever dogs [6].
Although dogs in the initial TTC8 study by Downs et al. [6] were not reported to have
other clinical and morphological features in addition to PRA, it has since been shown
that the 1-bp deletion in TTC8 leads to a syndromic PRA phenotype, with dogs exhibiting
signs of obesity, renal anomalies, sperm defects and olfactory defects [67]. For the SS,
no information regarding spermatozoa flagella potency in male dogs was available to
conclude if fertility defects are present. However, for proband SS5, the owner reported
that the bitch did not have a season until past the breed’s typical age, around the age of 5
years. Further follow-up of canine BBS2 models is required to understand the spectrum
and complexity of additional features, ideally throughout the dog’s lifetime with the ability
to monitor retinal and renal changes as well as weight tracking and fertility programs. As
with the BBS4 and TTC8 canine phenotypes, it is plausible that the BBS2 c.1222G>C SNV
causes a syndromic PRA in the SS. Typically, when studying canine PRA, a diagnosis is
limited to ophthalmoscopic evaluation. Distinguishing between a canine nonsyndromic
and syndromic condition requires recognition of multiple clinical signs, where additional
features can be challenging to quantify or assess. Changes in social dominance, olfactory
defects and learning or developmental delay are some of the behavioral and neurological
features displayed in BBS human patients and mouse models, which are challenging to
quantify in dogs. Further to this, obesity is a common problem in dogs, whereby 39–65%
of dogs are classified as overweight and between 9–20% are obese [68,69]. Therefore, its
association with a genetic disorder can easily be overlooked. Physical facets, including
craniofacial or dental features, are more pronounced; however, renal deficits would need
to be monitored by a veterinary surgeon to characterize. In future studies of canine PRA,
BBS genes’ involvement should be considered, particularly when a diagnosis is based on
ophthalmoscopy alone and information regarding physical or additional characteristics is
limited.
As oligogenic inheritance has been observed in human BBS [57], this prospect was
explored in the current study. The only notable exonic variant found to segregate in ad-
dition to the BBS2 SNV was a SNV in CEP290. CEP290 interacts with numerous ciliary
proteins and has been implicated in human BBS type-14 [70] in addition to a nonsyndromic
IRD, LCA [71]. The CEP290 SNV was present in SS of all three BBS2 genotypes (with five
SS homozygous for the BBS2 SNV also homozygous for the CEP290 SNV) in addition
to multiple dogs of other breeds, suggesting that this is probably an ancestral polymor-
phism. However, further genotyping of SSs is required to confirm this. It appears that the
BBS-phenotype in the SS is a single-gene recessive disorder caused by the exonic BBS2
c.1222G>C SNV, however, to exclude the involvement of intronic variants as potential
oligogenic contributors, such as triallelic or modifier mutations, targeted sequencing of
all BBS genes across numerous c.1222G>C homozygotes and non-affected SS controls,
or functional cDNA or RNA analysis on tissue from an affected dog would be required.
Furthermore, this analysis did not exclude the presence of intronic variants that may impact
splicing, including potential deep-intronic variants in other genes, due to the compelling
variant in BBS2.
The allele frequency of 0.021, when excluding third-generation relatives to the proband
from available pedigree information, indicates this is a rare variant and at a low frequency
in the current SS population. Despite this, sample collection showed the variant is still
present in the current UK population and SS populations elsewhere, and the availability
of a DNA test (termed BBS2-PRA) will raise awareness of this form of PRA. Utilization
of such a diagnostic test within the SS breeding community will reduce the possibility of
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future generations becoming affected with this form of PRA, with the potential to eliminate
this form of PRA from the gene pool possibly within the next few generations. The use of a
DNA test would provide genetic information on the status of this PRA-associated mutation
before clinical signs present, and therefore provide a tool for breeding choices before dogs
reach breeding age. Moreover, the absence of BBS2 c.1222G>C in additional PRA cases in
the screening cohort suggests at least one other form of PRA in the breed remains unsolved.
This provides an opportunity to explore PRA in the SS breed further.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/genes12111771/s1. Table S1: Variants associated with canine inherited retinal degenerations
(IRDs) and the methods used to exclude each variant as causal in proband SS1 before whole-genome
sequencing. Table S2: In-house effect scores assigned to sequence ontology terms used to prioritize
variant filtration in whole-genome sequencing analysis. Table S3: A list of twelve variants homozy-
gous in the affected dog that remained after filtering out non-common variants using the DBVDC.
An asterisks (*) highlights those variants overlapping with the 15 variants in the final filtering list
following candidate gene analysis in Table S4. Table S4: Fourteen variants identified through WGS
filtering to exclude in a SS cohort. Table S5: The number of individuals from each dog breed screened
for the BBS2 c.1222G>C and each sample origin. Figure S1: Pedigree drawing of proband SS1 shows
there is shared ancestry between five BBS2 c.1222G>C homozygotes. Male dogs are shown as a
square symbol and females as a circle symbol. Individuals colored pink are related within three
generations to the proband SS1. Figure S2: A schematic of the canine BBS2 protein. The N-terminal
(BBS2_N) is positioned between amino acid residues 22-120. The middle region domain (BBS2_M) is
located between amino acids 159-266. The C-terminal (BBS2_C) resides between amino acids 270-709
with a putative coiled-coil domain (CC) from 317-344 amino acids. The BBS2 candidate SNV affects
amino acid position 408, as highlighted by a red asterisk. File S1: List of keywords associated with
progressive retinal atrophy (PRA).
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